Molecular mechanisms of direct neuronal programming

直接神经元编程的分子机制

• 批准号: 8674398
• 负责人: Esteban Orlando Mazzoni
• 金额: $ 31.78万
• 依托单位: NEW YORK UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-01 至 2019-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8674398
• 关键词: Address; Axon; Binding; Bypass; Cell Therapy; Cells; Cephalic; Cervical; ChIP-seq; Chest; Chromatin; Clinic; Clinical; Communication; Complement; Consensus; Data; Development; Diagnostic; Disease; Environment; Epigenetic Process; Fibroblast Growth Factor; Future; Gene Expression; Generic Drugs; Genes; Genetic; Genomics; Goals; Hour; Implant; Knowledge; Lumbar spinal cord structure; Maps; Medical Research; Molecular; Motor Neurons; Mus; Muscle; Neuraxis; Neurons; Nucleic Acid Regulatory Sequences; Organ; Patients; Pattern; Population; Protocols documentation; Safety; Signal Transduction; Speed; Spinal; Spinal Cord; Spinal cord injury; Staging; Technology; Testing; Tissues; Translating; Transplantation; Uncertainty; base; cell type; clinical application; clinically relevant; design; embryonic stem cell; extracellular; histone modification; implantation; improved; in vivo; innovation; insight; knock-down; nerve supply; new technology; novel strategies; progenitor; programs; public health relevance; stem cell differentiation; stem cell technology; stem cell therapy; success; transcription factor; transcriptome sequencing

DESCRIPTION (provided by applicant): Embryonic stem cells (ESC) will revolutionize medical research and patient treatment. However, two major hurdles do not allow the rapid transition of ESC therapies to clinical settings: 1) the lack of protocols precluding homogenous cell populations that exactly reproduce those in vivo; 2) the uncertainty about the fate stability of ESC-derived cells after in vivo grafting. Overcoming these limitations will ameliorate safety concerns associated with ESC-derived cell therapies. Our long term goal is to efficiently generate ESC-derived cells that functionally integrate into organs. We have recently developed efficient protocols to derive terminal cell fates from ESC. When expressed in differentiating ESC, Ngn2- Isl1-Lhx3 (the NIL transcription factors) and Ngn2- Isl1-Phox2a (the NIP transcription factors) are sufficient to program spinal or cranial motor neuron identity respectively. This also happens extremely rapidly: Within 48 hours more than 97% of the cells acquire all the features of terminally differentiated motor neurons. Moreover, programmed neurons correctly integrate into the developing spinal cord projecting axons mirroring the endogenous neurons. Although, NIL and NIP factors do not provide the motor neuron subtype identity required for precise muscle innervation, our preliminary data suggests that it can be acquired by the activity of developmentally relevant signals. We hypothesize that NIL and NIP factors program "generic" motor neuron fate through a rapid transcriptional sequence, and that subtype identity can be independently imposed either by genetic factors or by the host environment after grafting. Here we propose 3 aims to test these ideas: Aim 1- To understand the molecular mechanisms of direct cell programming, we will map the NIL and NIP genetic and epigenetic requirements for efficient programming. This knowledge will facilitate the future design of programming strategies for different clinically relevant cell types. Aim 2- To increase the cellular precision of direct programming, we will impose subtype identity to NIL- programmed neurons by the activity of developmentally relevant signals or transcription factors. This novel strategy will generate neurons at a level of efficiency and precision compatible with clinical applications. Aim 3- To dissect the influence of the host tissue on ESC-derived neurons, we will test the cellular stability of NIL-programmed neurons after implantation into the spinal cord. These results will investigate if ESC-derived neurons change fate after interacting with the host tissue. Completing this proposal will impact not only future therapies for spinal cord injurie, but will also produce general principles to differentiate disease relevant cells at high efficiency These are necessary steps to accelerate the transition of ESC to clinical applications.

描述（由申请人提供）：胚胎干细胞（ESC）将彻底改变医学研究和患者治疗。然而，有两个主要障碍不允许 ESC 疗法快速过渡到临床环境：1）缺乏排除在体内精确复制同质细胞群的方案； 2）ESC衍生细胞体内移植后命运稳定性的不确定性。克服这些限制将改善与 ESC 衍生细胞疗法相关的安全问题。我们的长期目标是有效生成能够功能性整合到器官中的 ESC 衍生细胞。我们最近开发了有效的方案来从 ESC 获得终末细胞命运。当在分化的 ESC 中表达时，Ngn2-Isl1-Lhx3（NIL 转录因子）和 Ngn2-Isl1-Phox2a（NIP 转录因子）足以分别编程脊髓或颅运动神经元身份。这种情况发生得非常快：48 小时内，超过 97% 的细胞获得了终末分化运动神经元的所有特征。此外，编程的神经元正确地整合到发育中的脊髓中，投射轴突反映了内源性神经元。尽管 NIL 和 NIP 因子不能提供精确肌肉神经支配所需的运动神经元亚型身份，但我们的初步数据表明，它可以通过发育相关信号的活动来获得。我们假设 NIL 和 NIP 因子通过快速转录序列编程“通用”运动神经元命运，并且亚型身份可以由遗传因素或移植后的宿主环境独立施加。在这里，我们提出 3 个目标来测试这些想法： 目标 1 - 为了了解直接细胞编程的分子机制，我们将绘制有效编程的 NIL 和 NIP 遗传和表观遗传要求。这些知识将有助于未来针对不同临床相关细胞类型的编程策略的设计。目标 2-为了提高直接编程的细胞精度，我们将通过发育相关信号或转录因子的活动将亚型同一性强加给 NIL 编程神经元。这种新颖的策略将以与临床应用兼容的效率和精度水平生成神经元。目标 3-为了剖析宿主组织对 ESC 衍生神经元的影响，我们将测试 NIL 编程神经元在植入脊髓后的细胞稳定性。这些结果将调查 ESC 衍生的神经元在与宿主组织相互作用后是否改变命运。完成该提案不仅将影响未来脊髓损伤的治疗，还将产生高效分化疾病相关细胞的一般原则。这些是加速 ESC 向临床应用过渡的必要步骤。